secwatch.observer — SEC 8-K summary
======================================

Issuer:     RESMED INC (RMD)
CIK:        0000943819
Form:       8-K
Filed at:   2024-01-24T23:59:59+00:00
Accession:  0001193125-24-014223
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ResMed Q2 FY2024 revenue $1.16B (+12% YoY); non-GAAP EPS $1.88 (+13%)
---------------------------------------------------------------------

- Revenue $1,162.8M (+12% YoY, +11% constant currency); GAAP op profit down 2%, non-GAAP op profit up 20% to $365.5M.
- GAAP diluted EPS $1.42 (-7%); non-GAAP diluted EPS $1.88 (+13%), driven by revenue growth and cost discipline.
- Board declared $0.48/share quarterly cash dividend with record date Feb 8, payable March 14.
- Resumed share repurchase program; repurchased $50M of common stock during the quarter.
- Gross margin contracted 50 bps to 55.6% GAAP; non-GAAP gross margin improved 10 bps to 56.9%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/943819/000119312524014223/0001193125-24-014223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/943819/000119312524014223/d685328d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-014223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer